Atlas Trials

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Clinical trial NCT05516628 · RECRUITING

Trial details

NCT number
NCT05516628
Sponsor
National Cancer Centre, Singapore
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2023-02-28
Primary completion
2027-03-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.